Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
We use our state-of-the-art dedicated workflow for designing focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.
Several key aspects differentiate our library:
partner
Reaxense
upacc
O95452
UPID:
CXB6_HUMAN
Alternative names:
Connexin-30
Alternative UPACC:
O95452; B3KQN2; Q5Q1H9; Q5Q1I0; Q5Q1I1; Q5T5U0; Q8IUP0
Background:
Gap junction beta-6 protein, also known as Connexin-30, plays a pivotal role in cell communication. It forms gap junctions, facilitating the diffusion of low molecular weight materials between cells. This protein's structure and function are crucial for maintaining cellular homeostasis and supporting tissue function.
Therapeutic significance:
Connexin-30 is implicated in Ectodermal dysplasia 2, Clouston type, and various forms of sensorineural hearing loss. Its involvement in these conditions highlights its potential as a target for therapeutic intervention, aiming to alleviate symptoms or possibly cure these diseases.